
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: BL-B01D1; Drug: Pemetrexed+Cisplatin or Carboplatin
Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Not yet recruiting
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: BL-B01D1; Drug: Pemetrexed+Cisplatin or Carboplatin
Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Not yet recruiting
Background Digital mental health tools, including AI apps, are becoming popular for helping people with mental health issues. However, we need to understand how well these tools work for students…
The Benefits of Synthetic Data in AI Development In the fast-growing field of artificial intelligence (AI), having diverse and high-quality datasets is crucial. Synthetic data offers a practical solution to…
Practical Solutions and Value of Reinforcement Learning from Human Feedback (RLHF) Overview Large language models (LLMs) are versatile tools used in technology, healthcare, finance, and education to enhance workflows. Reinforcement…
Understanding the GRACE Risk Score Trial Results The GRACE Risk Score (GRS) is a tool used to help doctors assess the risk of serious heart problems in patients with suspected…
Title: Enhancing Clinic Efficiency Through AI Automation: A Strategic Partnership Approach By Dr. Maxwell Trenton, Head of AI Solutions at MedTech Innovators Ltd. Introduction: The Role of AI in Modern…
Study Overview OCD imposes significant burdens and has been exacerbated by the COVID-19 pandemic. This study aims to develop and validate a prevention program for at-risk adults utilizing cognitive-behavioral therapy…
Key Findings from the PhALLCON Study In March 2024, the FDA approved ponatinib for treating newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) alongside chemotherapy. This decision was…